Based on the scientific findings on the body’s own biological transport system, InnoMedica has developed a proprietary technology platform that enables the targeted distribution of drugs in the body. The transport system of InnoMedica is based on liposomes with an intelligent surface structure.
In order to make the biodistribution – i.e. the biological distribution of molecules in the body – medically useful, the functioning of the natural, endogenous logistics must be understood. The vesicles from InnoMedica are processed from originally natural building blocks (lipids) into liposomes. These are modeled on the natural vesicles in size and structure. However, the cargo is not an endogenous substance but a therapeutic agent.
The effect of the liposomal transport system can be further optimized by surface modifications and lipid compositions, but also by varying the particle size. These adjustments in the liposomal design should respond as well as possible to the different signals of the body depending on the application, for example to inflammations, more permeable blood vessels or deficiency symptoms in the nerve pathways.
The synthetic production of such biologically functional liposomes is typically associated with three major technical challenges:
Stability: The liposomes must be brought into a chemically and biologically stable form. InnoMedica uses a special manufacturing process to ensure a natural balance without the use of additional stabilizers.
Cargo: It must be possible to load the liposomes with therapeutically relevant amounts of the desired drug. Once the active substance is inside the liposome, it must be ensured that it does not leave the liposome again. Depending on the chemical profile of the active substance, InnoMedica has developed different procedures for loading the liposomes.
Reproducibility: Compliance with tolerance ranges in production can only be achieved with a stable, well characterized manufacturing process. It is a challenge to achieve constancy in the production of liposomes. The manufacturing process developed by InnoMedica meets the requirements of good manufacturing practice due to its simplicity and robustness.
For proven pharmaceuticals, improved efficacy is achieved with simultaneous reduction of side effects
The liver and kidneys quickly break down unpackaged, freely dissolved, exogenous substances such as drugs. The immune system also tries to protect the body from such foreign bodies. The lipid shell prevents the active substance from acting systemically throughout the body, thus protecting healthy tissue. The drug remains available for longer in the patient’s body in the blood stream, which can increase the desired therapeutic effect. Thanks to its protective function, InnoMedica’s technology reduces the side effects and, thanks to intelligent surface structures, also increases the therapeutic effect.
|The flexibility of the manufacturing process allows InnoMedica to build the liposomes in such a way that they can target different organs or cells in the body.|
|Composition of the shell: The mixing ratio of the lipid components in the liposome shell has a great influence on the biodistribution. Even small changes in the corresponding ratios can lead to significantly changed distribution profiles.|
|Size and size distribution of liposomes: The average size and size distribution of liposomes influences biodistribution and penetration into tissue. For example, there are organs such as the brain that are only accessible to very small liposomes.|
|Shape of the liposomes: Shape also plays an important role in the uptake. Spherical liposomes behave differently in the body than elliptical or tubular shaped liposomes.|
|Properties of the liposome surface: The liposome surface is of particular importance as the liposomes pass through the body to the target tissue. For navigation in the body, InnoMedica uses sugar molecules attached to the liposome in certain applications, which play an important role in the detection of certain tissue types or target cells.|
Various prototypes were investigated in preclinical trials, which differ in their liposomal design. InnoMedica has discovered a type that enables the crossing of the blood-brain barrier. In neurodegenerative diseases, for example, a regenerative agent can be delivered to the brain.
Since the products use active substances that are already in use in the clinic, the translation risk compared to conventional drug development of new active substances can be considered lower.